β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Autor: | Thompson, Philip A., O'Brien, Susan M., Xiao, Lianchun, Wang, Xuemei, Burger, Jan A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G. |
---|---|
Předmět: |
MICROGLOBULINS
LEUKEMIA RITUXIMAB CYCLOPHOSPHAMIDE FLUDARABINE ANTINEOPLASTIC agents CARCINOGENESIS ANTIMETABOLITES ANTIVIRAL agents BLOOD proteins BONE marrow CHROMOSOMES CHRONIC lymphocytic leukemia COMPARATIVE studies GLOBULINS HETEROCYCLIC compounds IMMUNOGLOBULINS LONGITUDINAL method RESEARCH methodology MEDICAL cooperation PROGNOSIS RESEARCH RESEARCH funding TRANSFERASES EVALUATION research TREATMENT effectiveness PROPORTIONAL hazards models RETROSPECTIVE studies CASE-control method |
Zdroj: | Cancer (0008543X); Feb2016, Vol. 122 Issue 4, p565-573, 9p |
Abstrakt: | |
Databáze: | Complementary Index |
Externí odkaz: |